UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $833,000 Stock Position in Liquidia Co. (NASDAQ:LQDA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in shares of Liquidia Co. (NASDAQ:LQDA) by 5.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 83,289 shares of the company’s stock after selling 4,361 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Liquidia were worth $833,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp boosted its holdings in shares of Liquidia by 18.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock valued at $2,496,000 after acquiring an additional 32,076 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Liquidia by 398.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,039 shares of the company’s stock worth $156,000 after purchasing an additional 10,421 shares during the last quarter. Deuterium Capital Management LLC bought a new stake in shares of Liquidia during the second quarter worth about $120,000. Rhumbline Advisers increased its stake in shares of Liquidia by 12.4% in the second quarter. Rhumbline Advisers now owns 80,164 shares of the company’s stock valued at $962,000 after buying an additional 8,871 shares during the period. Finally, Arizona State Retirement System raised its holdings in Liquidia by 10.7% in the 2nd quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock valued at $166,000 after buying an additional 1,341 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Trading Down 0.9 %

Shares of LQDA opened at $10.59 on Friday. The firm’s fifty day simple moving average is $10.91 and its two-hundred day simple moving average is $11.20. Liquidia Co. has a 12 month low of $7.76 and a 12 month high of $16.99. The stock has a market capitalization of $896.31 million, a P/E ratio of -6.50 and a beta of 0.22.

Insider Activity at Liquidia

In related news, insider Rajeev Saggar sold 2,260 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the transaction, the insider now directly owns 207,383 shares of the company’s stock, valued at $2,304,025.13. This represents a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Kaseta sold 3,892 shares of Liquidia stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $43,240.12. Following the completion of the sale, the chief financial officer now directly owns 311,076 shares of the company’s stock, valued at approximately $3,456,054.36. This trade represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,007 shares of company stock worth $245,780 in the last 90 days. Corporate insiders own 30.10% of the company’s stock.

Analyst Upgrades and Downgrades

LQDA has been the topic of a number of research reports. Lifesci Capital initiated coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. Scotiabank began coverage on Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Liquidia currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).